Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?
作者信息
Yang Shenmiao, Kay Neil E, Shi Min, Hanson Curtis A, Gale Robert Peter
机构信息
Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, China.
Mayo Clinic, Department of Medicine, Division of Hematology, Rochester, MN, USA.
出版信息
Leukemia. 2022 Nov;36(11):2743-2747. doi: 10.1038/s41375-022-01699-7. Epub 2022 Sep 13.
PMID:36100641
Abstract
摘要
Zotero 插件